[CAS NO. 65928-58-7]  Dienogest

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [65928-58-7]

Catalog
SLK-S1251
Brand
Selleck
CAS
65928-58-7

DESCRIPTION [65928-58-7]

Overview

MDL-
Molecular Weight311.42
Molecular FormulaC20H25NO2
SMILESC[C@@]12[C@]([C@]3(C(CC1)=C4C(CC3)=CC(=O)CC4)[H])(CC[C@]2(CC#N)O)[H]

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM3.2111 mL16.0555 mL32.1110 mL
5 mM0.6422 mL3.2111 mL6.4222 mL
10 mM0.3211 mL1.6055 mL3.2111 mL
50 mM0.0642 mL0.3211 mL0.6422 mL

Description

Dienogest (STS 557) is an orally active synthetic progesterone, used for contraception and the treatment of endometriosis.

Targets

progestogen Receptor [1]

In vitro

Dienogest activates progesterone receptor (EC50=3.4 or 10.5 nM) with antagonistic activity on androgen receptor (EC50=420.6 or 775.0 nM) but not agonistic nor antagonistic action on GR, MR (3000 nM). Dienogest combined with Oestradiol leads to an increase in the levels of prolactin mRNA and prolactin production in a dose-dependent manner in human endometrial stromal cells (ESC). Dienogest directly acts on endometrial tissue in progestogenic response, such as decidualization, increases prolactin production and growth retardation. Dienogest at concentration of 0.1 μM and 1 μM significantly inhibits BrdU incorporation into DNA at 24 and 48 hours in the cultured endometriotic stromal cells. Dienogest significantly increases the cells in G0/G1 phase and reduces the cells in S phase and G2/M phase in 24 and 48 hours in the cultured endometriotic stromal cells.

In vivo

Dienogest (0.1-1 mg/kg per day, p.o.) reduces the endometrial implant volume to the same extent as Danazol (100 mg/kg per day, p.o.) in rats. Dienogest ameliorates the endometrial implant-induced alterations of the immune system: i.e. it increases the natural killer activity of peritoneal fluid cells and splenic cells, decreases the number of peritoneal fluid cells, and decreases interleukin-1beta production by peritoneal macrophages. Dienogest (0.1 mg/kg per day) combined with Buserelin (0.3 mg/kg per day) suppresses the bone mineral loss induced by buserelin alone, with no reduction of the effect on endometrial implants.


Synonyms

19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17α)-
(17α)-17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile
STS 557
Dienogest
Dienogestril
17α-Cyanomethyl-17β-hydroxyestra-4, 9-dien-3-one
Dinagest